Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MITO

Stealth BioTherapeutics (MITO) Stock Price, News & Analysis

Stealth BioTherapeutics logo

About Stealth BioTherapeutics Stock (NASDAQ:MITO)

Advanced Chart

Key Stats

Today's Range
$0.32
$0.32
50-Day Range
$0.31
$0.32
52-Week Range
$0.16
$1.03
Volume
N/A
Average Volume
946,105 shs
Market Capitalization
$23.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.

Receive MITO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stealth BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

MITO Stock News Headlines

This document could hand you a shot at $915 every single weekend!
Something fascinating happens in the options market when most traders aren't paying attention… While everyone else collects standard daily premiums Monday through Friday... There's a special opportunity to target TRIPLE premiums just for holding positions over the weekend. Think about that... Most traders get one day's worth of premium for their trades. But by entering right before the weekend, when everything works out, you could collect THREE days worth - even though markets are closed for two of them. Thanks to a special discovery by a Wall Street legend who helped manage a $1.7 trillion firm – regular folks like you can now target extra cash from the markets on weekends… Just like he showed his small group of traders on December 20th with KO... A quick 2-minute setup Friday afternoon… Head out for the weekend... Monday morning? An extra $1,111 sitting in the account (with a $5k starting stake).
See More Headlines

MITO Stock Analysis - Frequently Asked Questions

Stealth BioTherapeutics Corp (NASDAQ:MITO) released its quarterly earnings data on Thursday, August, 5th. The company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by $0.01.

Stealth BioTherapeutics (MITO) raised $81 million in an initial public offering on Friday, February 15th 2019. The company issued 6,200,000 shares at a price of $12.00-$14.00 per share. Jefferies, Evercore ISI and BMO Capital Markets acted as the underwriters for the IPO and Nomura was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Stealth BioTherapeutics investors own include Tesla (TSLA), TherapeuticsMD (TXMD), NIO (NIO), Plug Power (PLUG), Allena Pharmaceuticals (ALNA), SCYNEXIS (SCYX) and Tonix Pharmaceuticals (TNXP).

Company Calendar

Last Earnings
8/05/2021
Today
5/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MITO
Fax
N/A
Employees
29
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$52.53 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$21.09 million
Price / Cash Flow
N/A
Book Value
($0.79) per share
Price / Book
-0.41

Miscellaneous

Free Float
N/A
Market Cap
$23.54 million
Optionable
Not Optionable
Beta
1.46
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:MITO) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners